Education
About Us
Working with TipRanks
Follow Us
Citius Pharmaceuticals (CTXR)
NASDAQ:CTXR
CTXR Stock Chart & Stats
$0.86
-$0.64(-14.59%)
At close: 4:00 PM EST
$0.86
-$0.64(-14.59%)
Day’s Range― - ―
52-Week Range$0.63 - $3.69
Previous CloseN/A
Volume111.57K
Average Volume (3M)1.16M
Market Cap
$17.91M
Enterprise Value$0.00
Total Cash (Recent Filing)$4.25M
Total Debt (Recent Filing)$1.81M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Feb 06, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding20,762,917
10 Day Avg. Volume511,305
30 Day Avg. Volume1,160,981
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe company reported positive top-line data from the P3 study, achieving its primary endpoint of increase in time to catheter failure.
Commercialization PotentialCitius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.
Regulatory GuidanceThe FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.
Bears Say
Capital RequirementsCitius Pharma needs to secure additional capital prior to a launch of Lymphir.
Financial ConstraintsThe company's recent quarterly report suggests the need for additional capital in the immediate future to support operations.
Regulatory Approval TimelineCompleting the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.
Citius Pharmaceuticals News
CTXR FAQ
What was Citius Pharmaceuticals’s price range in the past 12 months?
Citius Pharmaceuticals lowest stock price was $0.63 and its highest was $3.69 in the past 12 months.
What is Citius Pharmaceuticals’s market cap?
Citius Pharmaceuticals’s market cap is $17.91M.
When is Citius Pharmaceuticals’s upcoming earnings report date?
Citius Pharmaceuticals’s upcoming earnings report date is Feb 06, 2026 which is in 21 days.
How were Citius Pharmaceuticals’s earnings last quarter?
Citius Pharmaceuticals released its earnings results on Dec 23, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.42.
Is Citius Pharmaceuticals overvalued?
According to Wall Street analysts Citius Pharmaceuticals’s price is currently Overvalued.
Does Citius Pharmaceuticals pay dividends?
Citius Pharmaceuticals does not currently pay dividends.
What is Citius Pharmaceuticals’s EPS estimate?
Citius Pharmaceuticals’s EPS estimate is 0.43.
How many shares outstanding does Citius Pharmaceuticals have?
Citius Pharmaceuticals has 20,762,917 shares outstanding.
What happened to Citius Pharmaceuticals’s price movement after its last earnings report?
Citius Pharmaceuticals reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went down -23.077%.
Which hedge fund is a major shareholder of Citius Pharmaceuticals?
Currently, no hedge funds are holding shares in CTXR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Citius Pharmaceuticals
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Technical Analysis
Ownership Overview
2.36%
Insiders
3.51% Mutual Funds
0.03% Other Institutional Investors
93.52% Public Companies and
Individual Investors